Sfoglia per AUTORE
CROOK T
Collezione AO Cuneo

  

Items : 8

Inhibition of the angiotensin II type 2 receptor AT(2)R is a novel therapeutic strategy for glioblastoma. in Proceedings of the National Academy of Sciences of the United States of America / Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2116289119. doi: 10.1073/pnas.2116289119. Epub 2022 Au

2022
AO Cuneo

Perryman R; Renziehausen A; Shaye H; Kostagianni AD; Tsiailanis AD; Thorne T; Chatziathanasiadou MV; Sivolapenko GB; El Mubarak MA; Han GW; Zarzycka B; Katritch V; Lebon G; Lo Nigro C; Lattanzio L; Morse SV; Choi JJ; O'Neill K; Kanaki Z; Klinakis A; Crook T; Cherezov V; Tzakos AG; Syed N;

Expression and subcellular localization of the bromodomain-containing protein 7 is a prognostic biomarker in breast cancer. in Anti-cancer drugs / Anticancer Drugs. 2020 Apr;31(4):423-430. doi: 10.1097/CAD.0000000000000897.

2020
AO Cuneo

Garrone O; Vivenza D; Brizio R; Mantovani F; Del Sal G; Merlano M; Crook T; Lo Nigro C;

The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention. in Oncogene / Oncogene. 2019 Mar;38(13):2320-2336. doi: 10.1038/s41388-018-0563-y. Epub 2018 Nov 26.

2019
AO Cuneo

Tzakos AG; Proby C; Stebbing J; Fleming C; Szlosarek P; Thompson A; Evans A; O'Neill K; Sim VR; Li S; Harwood C; Matin R; Hajji N; Del Carmen Fernandez-Carranco M; Vega-Rioja A; Merlano M; Lattanzio L; Nigro CL; Weir L; Rao B; Wang H; Renziehausen A; Syed N; Crook T;

DUSP2 methylation is a candidate biomarker of outcome in head and neck cancer. in Annals of translational medicine / Ann Transl Med. 2018 Jul;6(13):271. doi: 10.21037/atm.2018.06.39.

2018
AO Cuneo

Lo Nigro C; Vivenza D; Denaro N; Lattanzio L; Fortunato M; Crook T; Merlano MC;

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. in Journal of translational medicine / J Transl Med. 2016 Jul 25;14(1):65. doi: 10.1186/s12967-016-0791-2.

2016
AOU Città della Salute di Torino
AO Cuneo
AOU Novara

Topalian SL; Taube JM; Drake CG; Pardoll DM; Cheadle C; Cope L; Xu H; Fan J; Pritchard TS; Netto GJ; Anders RA; Danilova L; McMiller TL; Berger AE; Ascierto ML; Formenti S; De Biasio V; Battarra VC; Michelozzi P; Nudo M; Marino C; Bono R; Capuano M; Zappalà A; Passarelli F; Caggiati A; Mastroeni S; Fortes C; Anniciello A; et alii...

p53 family members and chemoresistance in cancer: what we know and what we need to know. in Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy / Drug Resist Updat. 2003 Dec;6(6):323-8. doi: 10.1016/j.drup.2003.11.001.

2003
AO Cuneo

Crook T; Gasco M;

Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. in Oncogene / Oncogene. 2002 Mar 14;21(12):1876-81. doi: 10.1038/sj.onc.1205256.

2002
AO Cuneo

Tidy JA; Repellin C; Brooks L; Farrell PJ; Sullivan A; Gasco M; Dunne B; Gusterson B; Evans DJ; Crook T;

Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. in Cancer research / Cancer Res. 2002 Apr 1;62(7):2072-6.

2002
AO Cuneo

Merlano M; Yulug I; Numico G; Hiller L; Smith P; Sullivan A; Heath V; Bell AK; Gasco M; Farrell PJ; Tavassoli M; Gusterson B; Crook T;